391 related articles for article (PubMed ID: 11803198)
1. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
2. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
6. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Farlow MR
Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
[TBL] [Abstract][Full Text] [Related]
7. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
Amici S; Lanari A; Romani R; Antognelli C; Gallai V; Parnetti L
Mech Ageing Dev; 2001 Nov; 122(16):2057-62. PubMed ID: 11589922
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Rösler M
Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
[TBL] [Abstract][Full Text] [Related]
10. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
11. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
12. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
13. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
[TBL] [Abstract][Full Text] [Related]
14. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
[No Abstract] [Full Text] [Related]
15. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
16. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Stahl SM
J Clin Psychiatry; 2000 Oct; 61(10):710-1. PubMed ID: 11078030
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
Macdonald IR; Rockwood K; Martin E; Darvesh S
J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine in vascular dementia.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
[TBL] [Abstract][Full Text] [Related]
19. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
20. New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications?
J Clin Psychiatry; 2000 Apr; 61(4):307-15. PubMed ID: 10830158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
